Abviva, Inc.: New Case Of Mad Cow Disease Detected In North America

Main Category: CJD / vCJD / Mad Cow Disease
Article Date: 03 Jul 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Abviva, Inc. (OTCBB: AVVA) announced that BioBDC International (BioBDC), Abviva's exclusive sales agent for Mad Cow diagnostic tests produced by Abviva's subsidiary company Prion Developmental Laboratories, Inc. (PDL), reported the Canadian Food Inspection Agency confirmed a new case of mad cow disease, bovine spongiform encephalopathy (BSE), was discovered in western Canada, increasing consumer's concerns over beef safety.

This discovery came only two weeks after over 100,000 South Korean's protested against their government's agreement to re-start importing U.S. beef. Many South Korean's fear U.S. beef is not safe citing concerns that most U.S beef is not tested for BSE.

PDL developed a fast and inexpensive on-site diagnostic test that can increase consumer protection by determining if cattle are infected with Mad Cow Disease. The estimated cost to consumers for this added protection is less than $0.05 per pound.

For more information on Mad Cow Disease and on PDL's BSE Rapid Assays please go to BioBDC's website: http://www.biobdc.com.

About BioBDC International.

BioBDC is a private corporation in Vancouver, British Columbia, Canada formed to distribute PDL's Mad Cow Disease test.

About PDL, Inc.

PDL develops rapid, low cost diagnostic tests for BSE and other animal diseases caused by prions.

About Abviva, Inc.

Abviva, Inc. is a biomedical company established to develop and commercialize diagnostic and therapeutic products, including PDL's Rapid Assays.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Abviva, Inc.